/stocks — the workspaceLOADING
All NBP SEC filings, by type → · Earnings date & implied move · Search inside filings
NovaBridge Biosciences (NBP) is a pharmaceutical preparations company. Piotroski F-Score 5/7. 6 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind NBP’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2023-12-31 vs 2022-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Per ADS: one ADS is 23 ordinary shares (20-F filed 2026-04-07), so EPS and book value are multiplied by 23 and the share count divided by it.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from NBP’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on NBP plus an auto-SWOT — built from NBP's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate NBP using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has NBP been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as NBP tagged it: revenue us-gaap:Revenues, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, with EPS multiplied to a per-ADS figure, as its chart title says, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
Projected from NBP's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentNBP files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No lawmaker has disclosed a trade in NBP under the STOCK Act.
Total return including reinvested dividends, from NBP’s adjusted closing prices. Past return is not a forecast and not investment advice.
None of the 5 estimators could run on NBP's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for NBP. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for NBP, so sector medians could not fill the gaps.
Every refusal recorded for NBP → · How often we decline, and why →
No tracked institution reported a position in NBP in the latest 13F round.
Head office: Rockville, Maryland, United States · the company’s charter and its head office are in different countries.
Source: the cover page of NovaBridge Biosciences’s 20-F filed 2026-04-07, on EDGAR. Filings checked 2026-10-26. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Of 7 sales in the last ~6 months, 0 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 7 were filed without it.
| Dennis Phillip AndrewChief Medical Officer | SELL | $6K | view → |
| Cao Sean WuxiongChief Bus. Development Officer | SELL | $80K | view → |
| Xu Cong ClaireEVP, Clinical Development | SELL | $3K | view → |
| Xu Cong ClaireSVP, Clinical Development | SELL | $4K | view → |
| Dennis Phillip AndrewChief Medical Officer | SELL | $6K | view → |
| Xu Cong ClaireSVP, Clinical Development | SELL | $14K | view → |
| Cao Sean WuxiongSee Remarks | SELL | $43K | view → |
1 of the 2 checks that ran found nothing new for NBP; 1 found something. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.